Mersana Therapeutics Inc Stock Price, News & Analysis

Mersana Therapeutics (Nasdaq: MRSN) entered into a definitive merger agreement to be acquired by Day One Biopharmaceuticals for $25.00 per share cash upfront plus contingent value rights (CVRs) payable up to $30.25 per share, representing an aggregate deal value of up to approximately $285 million and an equity value of about $129 million at closing. Closing is expected by end of January 2026. The Mersana board unanimously recommends tendering shares; Mersana will become a wholly owned subsidiary and its common stock will be delisted upon closing.

Mersana Therapeutics (NASDAQ: MRSN) announced it will report business updates and third quarter 2025 financial results for the period ended September 30, 2025 on Friday, November 14, 2025.

The company will host a conference call and live webcast on November 14, 2025 at 8:00 a.m. Eastern Time. Domestic dial-in is 833-255-2826, international dial-in is 412-317-0689. A replay of the webcast will be available on the Investors & Media section of www.mersana.com for approximately 90 days following the call.

Mersana Therapeutics (NASDAQ:MRSN) reported Q2 2025 financial results and provided updates on its clinical programs. The company has enrolled over 45 patients in Emi-Le Phase 1 dose expansion cohorts for triple-negative breast cancer (TNBC). Key financial metrics include $77.0 million in cash and cash equivalents, with a net loss of $24.3 million ($4.87 per share).

Notable developments include a $15 million milestone payment from GSK for XMT-2056 development, completion of a 1-for-25 reverse stock split, and regaining Nasdaq compliance. The company expects its current capital to support operations into mid-2026. Initial clinical data from Emi-Le expansion cohorts is planned for release in H2 2025.

[ "Achieved $15 million development milestone payment from GSK collaboration", "Successfully regained Nasdaq compliance following reverse stock split", "Strong enrollment with over 45 TNBC patients in Emi-Le Phase 1 expansion cohorts", "Cash runway extended into mid-2026", "Collaboration revenue increased to $3.1M from $2.3M year-over-year", "Reduced G&A expenses by 29% to $7.4M from $10.5M year-over-year" ]

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, will host its Q2 2025 earnings conference call on August 13, 2025, at 8:00 a.m. ET. The company will provide business updates and financial results for the quarter ended June 30, 2025.

Investors can access the call via phone at 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast will be available on Mersana's website, with a replay accessible for approximately 90 days after the call.

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, has announced a 1-for-25 reverse stock split effective July 25, 2025. The split will reduce outstanding shares from 124.8 million to approximately 5.0 million.

The primary goal is to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement. Trading on a split-adjusted basis will begin July 28, 2025, under the same ticker "MRSN". The split won't affect the number of authorized shares or par value, and proportionate adjustments will be made to equity incentive plans. Computershare Trust Company will serve as the exchange agent.

Mersana Therapeutics (NASDAQ: MRSN) announced positive interim Phase 1 clinical data for their B7-H4-directed Dolasynthen ADC, Emi-Le (XMT-1660), at ASCO 2025. The drug showed a 31% confirmed objective response rate across B7-H4 high tumors at intermediate doses, and 44% confirmed ORR in patients with ≤4 prior lines of therapy. Notable results include a 56% ORR in ACC-1 patients regardless of dose and B7-H4 expression. The safety profile remained consistent with previous reports, with no new safety signals observed. The trial focused on various cancers including triple-negative breast cancer, HR+/HER2- breast cancer, ovarian cancer, endometrial cancer, and ACC-1. The FDA has granted two Fast Track designations for Emi-Le in advanced/metastatic triple-negative breast cancer and HER2 low/negative breast cancer post-topo-1 ADC treatments.

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 2:00 p.m. ET, and deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:00 p.m. ET. Both events will be webcast live and available on Mersana's website, with replays accessible for approximately 90 days.

Mersana Therapeutics (NASDAQ: MRSN) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug Emi-Le showed promising results in treating cancer patients with B7-H4 high tumors, achieving a 31% objective response rate across tumor types. In triple-negative breast cancer (TNBC) patients with B7-H4 high expression who received prior topo-1 ADC treatment, Emi-Le demonstrated a 29% response rate with median PFS of 16.0 weeks. The company's financial position shows $102.3 million in cash as of March 31, 2025, with runway expected into mid-2026. Q1 2025 resulted in a net loss of $24.1 million ($0.19 per share) compared to $19.3 million in Q1 2024. Mersana plans to report initial expansion cohort data in H2 2025.

Mersana Therapeutics (MRSN) presented updated clinical data for Emi-Le, their B7-H4-directed Dolasynthen ADC, at ESMO Breast Cancer 2025. The data showed an increased ORR of 31% across tumor types in B7-H4 high tumors at intermediate doses. For TNBC patients with B7-H4 high expression who received ≤4 prior treatments, the data revealed a 29% ORR, median PFS of 16.0 weeks, and median OS not yet reached. The company is advancing two dose expansion cohorts: "Dose A" at 67.4 mg/m² Q4W and "Dose B" starting at 44.5 mg/m² with escalation to 80 mg/m². Initial expansion data is expected in H2 2025. Financially, Mersana reported $102.3 million in cash as of March 31, 2025, with runway into mid-2026. Q1 2025 showed collaboration revenue of $2.8 million and a net loss of $24.1 million ($0.19 per share).